Request Deal Involvement
Gilead Sciences completed the acquisition of CymaBay Therapeutics for $4.3bn.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
pr advisors
LifeSci Partners
financial advisors
Centerview Partners
financial advisors
Lazard
legal advisors to financial advisors
Skadden Arps Slate Meagher & Flom
legal advisors
Cravath Swaine & Moore
financial advisors
Guggenheim Partners
financial advisors
Bank of America
legal advisors
Davis Polk & Wardwell
legal advisors to financial advisors
Debevoise & Plimpton
or
Principals
target
CYMABAY THERAPEUTICS
bidder
GILEAD SCIENCES
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite